Literature DB >> 6840202

Progress through G1 and S in relation to net protein accumulation in human NHIK 3025 cells.

O W Rønning, T Lindmo.   

Abstract

We have investigated whether human NHIK 3025 cells are dependent upon a net increase in cellular protein content in order to traverse G1 and S. The increase in DNA and protein content was studied by means of two-parameter flow cytometry using populations of cells synchronized by mitotic selection. By adding 1 microM cycloheximide to the medium protein synthesis was partially inhibited, resulting in negligible net accumulation of protein. The cells were able to enter S and progress through S under such conditions. The latter was the case whether the cells had been accumulating protein during G1 or not. The results further indicate that the larger cells enter S earlier and traverse S at a higher rate than the smaller cells. Our conclusion is that net accumulation of protein does not seem to be a prerequisite for traverse through G1 and S, i.e. DNA replication may be dissociated from the general growth of cell mass.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840202     DOI: 10.1016/0014-4827(83)90451-2

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Effect of two pyrimidine analogs on accumulation of tubulin in NHIK 3025 cells.

Authors:  M E Juul; J M Dornish; N O Juul; E O Pettersen; R Oftebro
Journal:  Mol Cell Biochem       Date:  1990-08-10       Impact factor: 3.396

2.  Multipolar mitotic cells in the human cell line NHIK 3025 following treatment with the mitotic inhibitor NY 4137.

Authors:  M E Juul; J M Dornish; P E Schwarze; E O Pettersen; R Oftebro
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

3.  Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H).

Authors:  E O Pettersen; R O Larsen; J M Dornish; B Børretzen; M E Juul; T E Aastveit; J M Nesland; E K Rofstad; R Oftebro
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.